CD8A and myeloid sarcoma: Taken together, these data demonstrate that although the overall distribution of memory CD8 T cell subsets was similar, SARS-CoV-2 mRNA vaccination induced a more robust antigen-specific CD8 T cell response in patients with MS treated with aCD20 compared to healthy controls, in particular after the second dose of the vaccine.